Company profile
Crucible Therapeutics
Transformational therapies for neurodegenerative diseases
- Industry
- Biotechnology Research
- Employees
- 7
Crucible Therapeutics company summary
Crucible Therapeutics is a company in the Biotechnology Research industry. On LinkedIn the company has around 7 employees.
What technology does Crucible Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Crucible Therapeutics
Crucible brings together a highly collaborative team of R&D experts and biotech entrepreneurs. With deep expertise across research, development, and commercialization, we are dedicated to advancing innovative RNA-based therapies to transform patient outcomes. Our breakthrough treatment programmes aim to halt degenerative conditions such as Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Crucible is developing novel therapies that prevent rogue nuclear RNAs from escaping into the cytoplasm where they drive toxic gain-of-functions and cell damage. Our approach disrupts the production of toxic dipeptide repeats (DPRs) and TDP-43 aggregates, which are relevant to both C9ORF72- and Sporadic-ALS populations and potentially other neurodegenerative diseases. Crucible Therapeutics was founded in 2023 to advance ground breaking innovations in neuroscience, originating from the Sheffield Institute for Translational Neuroscience (SITraN) and the Division of Neuroscience at the University of Sheffield, UK.
Compare companies similar to Crucible Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Crucible Therapeutics crucible-tx.com | Biotechnology Research | 7 | - | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Crucible Therapeutics
What does Crucible Therapeutics do?
Crucible brings together a highly collaborative team of R&D experts and biotech entrepreneurs. With deep expertise across research, development, and commercialization, we are dedicated to advancing innovative RNA-based therapies to transform patient outcomes. Our breakthrough treatment programmes aim to halt degenerative conditions such as Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Crucible is developing novel therapies that prevent rogue nuclear RNAs from escaping into the cytoplasm where they drive toxic gain-of-functions and cell damage. Our approach disrupts the production of toxic dipeptide repeats (DPRs) and TDP-43 aggregates, which are relevant to both C9ORF72- and Sporadic-ALS populations and potentially other neurodegenerative diseases. Crucible Therapeutics was founded in 2023 to advance ground breaking innovations in neuroscience, originating from the Sheffield Institute for Translational Neuroscience (SITraN) and the Division of Neuroscience at the University of Sheffield, UK.
How many employees does Crucible Therapeutics have?
Crucible Therapeutics has around 7 employees on LinkedIn.
Build a lead list from companies like Crucible Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.